Merz Pharma GmbH & Co. KGaA Sustainability Profile
Merz Pharma GmbH & Co. KGaA, commonly referred to as Merz, is a leading global healthcare company headquartered in Frankfurt, Germany. Founded in 1908, Merz has established a strong presence in the pharmaceutical and medical aesthetics industries, focusing on innovative solutions for neurological disorders, dermatology, and aesthetic medicine. With a commitment to research and development, Merz offers a diverse portfolio of products, including the renowned Xeomin® for neuromodulation and Belotero® for dermal fillers. These offerings are distinguished by their unique formulations and efficacy, catering to both healthcare professionals and patients. Merz has achieved significant milestones, including expansion into key international markets, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in patient care, making it a notable player in the global pharmaceutical landscape.
DitchCarbon Score
How does Merz Pharma GmbH & Co. KGaA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharma GmbH & Co. KGaA's score of 47 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Merz Pharma GmbH & Co. KGaA, headquartered in Germany, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Merz GmbH & Co. KGaA, which may influence its climate commitments and performance metrics. As of now, there are no documented reduction targets or climate pledges from Merz Pharma GmbH & Co. KGaA, nor are there any emissions data inherited from parent or related organizations. This lack of specific emissions data and reduction initiatives suggests that the company may still be in the early stages of formalising its climate strategy. In the context of the pharmaceutical industry, companies are increasingly expected to set ambitious targets for reducing greenhouse gas emissions across all scopes (Scope 1, 2, and 3). However, without specific commitments or data, it is unclear how Merz Pharma GmbH & Co. KGaA plans to align with these industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 2,088,000 | 0,000,000 |
| Scope 2 | 771,000 | 000,000 |
| Scope 3 | 36,782,000 | 00,000,000 |
How Carbon Intensive is Merz Pharma GmbH & Co. KGaA's Industry?
How Carbon Intensive is Merz Pharma GmbH & Co. KGaA's Location?
Merz Pharma GmbH & Co. KGaA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Merz Pharma GmbH & Co. KGaA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Sciton Inc.
Candela Medical, Inc.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.